Friday, 13 November 2026European Markets

IDEX BIOMETRICS Stock Was Up By 11.35% Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) rising 11.35% to kr0.20 on Friday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.4% to kr1,449.34, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

IDEX BIOMETRICS's last close was kr0.18, 94.33% under its 52-week high of kr3.23.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless smart cards, that includes financial payment and access control cards, as well as card-based devices for the storage of digital currencies. It primarily serves smart card manufacturers and similar solution integrators. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.07.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -217.51%.

Moving Average

IDEX BIOMETRICS's worth is way under its 50-day moving average of kr0.67 and way below its 200-day moving average of kr1.62.

Yearly Top and Bottom Value

IDEX BIOMETRICS's stock is valued at kr0.20 at 22:30 EST, way under its 52-week high of kr3.23 and way higher than its 52-week low of kr0.17.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IDEX BIOMETRICS's stock is considered to be overbought (>=80).

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com